Cuc H Tran1, Joe Brew2, Nicholas Johnson2, Kathleen A Ryan3, Brittany Martin4, Catherine Cornett4, Brad Caron4, R Paul Duncan5, Parker A Small3, Paul D Myers4, J Glenn Morris6. 1. College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. 2. College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States; Florida Department of Health in Alachua County, Gainesville, FL, United States. 3. College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States; College of Medicine, University of Florida, Gainesville, FL, United States. 4. Florida Department of Health in Alachua County, Gainesville, FL, United States. 5. College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States. 6. College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States; College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: JGMorris@epi.ufl.edu.
Abstract
BACKGROUND: School-located influenza vaccination (SLIV) programs are a promising strategy for increasing vaccination coverage among schoolchildren. However, questions of economic sustainability have dampened enthusiasm for this approach in the United States. We evaluated SLIV sustainability of a health department led, county-wide SLIV program in Alachua County, Florida. Based on Alachua's outcome data, we modeled the sustainability of SLIV programs statewide using two different implementation costs and at different vaccination rates, reimbursement amount, and Vaccines for Children (VFC) coverage. METHODS: Mass vaccination clinics were conducted at 69 Alachua County schools in 2013 using VFC (for Medicaid and uninsured children) and non-VFC vaccines. Claims were processed after each clinic and submitted to insurance providers for reimbursement ($5 Medicaid and $47.04 from private insurers). We collected programmatic expenditures and volunteer hours to calculate fixed and variable costs for two different implementation costs (with or without in-kind costs included). We project program sustainability for Florida using publicly available county-specific student populations and health insurance enrollment data. RESULTS: Approximately 42% (n=12,853) of pre-kindergarten - 12th grade students participated in the SLIV program in Alachua. Of the 13,815 doses provided, 58% (8042) were non-VFC vaccine. Total implementation cost was $14.95/dose or $7.93/dose if "in-kind" costs were not included. The program generated a net surplus of $24,221, despite losing $4.68 on every VFC dose provided to Medicaid and uninsured children. With volunteers, 99% of Florida counties would be sustainable at a 50% vaccination rate and average reimbursement amount of $3.25 VFC and $37 non-VFC. Without volunteers, 69% of counties would be sustainable at 50% vaccination rate if all VFC recipients were on Medicaid and its reimbursement increased from $5 to $10 (amount private practices receive). CONCLUSIONS AND RELEVANCE: Key factors that contributed to the sustainability and success of an SLIV program are: targeting privately insured children and reducing administration cost through volunteers. Counties with a high proportion of VFC eligible children may not be sustainable without subsidies at $5 Medicaid reimbursement.
BACKGROUND: School-located influenza vaccination (SLIV) programs are a promising strategy for increasing vaccination coverage among schoolchildren. However, questions of economic sustainability have dampened enthusiasm for this approach in the United States. We evaluated SLIV sustainability of a health department led, county-wide SLIV program in Alachua County, Florida. Based on Alachua's outcome data, we modeled the sustainability of SLIV programs statewide using two different implementation costs and at different vaccination rates, reimbursement amount, and Vaccines for Children (VFC) coverage. METHODS: Mass vaccination clinics were conducted at 69 Alachua County schools in 2013 using VFC (for Medicaid and uninsured children) and non-VFC vaccines. Claims were processed after each clinic and submitted to insurance providers for reimbursement ($5 Medicaid and $47.04 from private insurers). We collected programmatic expenditures and volunteer hours to calculate fixed and variable costs for two different implementation costs (with or without in-kind costs included). We project program sustainability for Florida using publicly available county-specific student populations and health insurance enrollment data. RESULTS: Approximately 42% (n=12,853) of pre-kindergarten - 12th grade students participated in the SLIV program in Alachua. Of the 13,815 doses provided, 58% (8042) were non-VFC vaccine. Total implementation cost was $14.95/dose or $7.93/dose if "in-kind" costs were not included. The program generated a net surplus of $24,221, despite losing $4.68 on every VFC dose provided to Medicaid and uninsured children. With volunteers, 99% of Florida counties would be sustainable at a 50% vaccination rate and average reimbursement amount of $3.25 VFC and $37 non-VFC. Without volunteers, 69% of counties would be sustainable at 50% vaccination rate if all VFC recipients were on Medicaid and its reimbursement increased from $5 to $10 (amount private practices receive). CONCLUSIONS AND RELEVANCE: Key factors that contributed to the sustainability and success of an SLIV program are: targeting privately insured children and reducing administration cost through volunteers. Counties with a high proportion of VFC eligible children may not be sustainable without subsidies at $5 Medicaid reimbursement.
Authors: Allison Kempe; Matthew F Daley; Jennifer Pyrzanowski; Tara M Vogt; Elizabeth J Campagna; L Miriam Dickinson; Simon J Hambidge; Judith C Shlay Journal: Acad Pediatr Date: 2014 May-Jun Impact factor: 3.107
Authors: Ginny E Cummings; Elizabeth Ruff; Stephen H Guthrie; Margaret A Hoffmaster; Larry L Leitch; James C King Journal: Pediatrics Date: 2012-03 Impact factor: 7.124
Authors: Evgeniya Antonova; Christopher S Ambrose; David Kern; Stan L Block; Herve Caspard; Ozgur Tunceli Journal: Vaccine Date: 2014-07-18 Impact factor: 3.641
Authors: Niranjan Bhat; Jennifer G Wright; Karen R Broder; Erin L Murray; Michael E Greenberg; Maleeka J Glover; Anna M Likos; Drew L Posey; Alexander Klimov; Stephen E Lindstrom; Amanda Balish; Marie-jo Medina; Teresa R Wallis; Jeannette Guarner; Christopher D Paddock; Wun-Ju Shieh; Sherif R Zaki; James J Sejvar; David K Shay; Scott A Harper; Nancy J Cox; Keiji Fukuda; Timothy M Uyeki Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy S Cox Journal: MMWR Recomm Rep Date: 2008-08-08
Authors: Katherine A Poehling; H Keipp Talbot; John V Williams; Yuwei Zhu; John Lott; Lori Patterson; Kathryn M Edwards; Marie R Griffin Journal: Vaccine Date: 2009-02-24 Impact factor: 3.641
Authors: Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini Journal: Am J Epidemiol Date: 2009-08-13 Impact factor: 4.897
Authors: Richard G Pebody; Helen K Green; Nick Andrews; Nicola L Boddington; Hongxin Zhao; Ivelina Yonova; Joanna Ellis; Sophia Steinberger; Matthew Donati; Alex J Elliot; Helen E Hughes; Sameera Pathirannehelage; David Mullett; Gillian E Smith; Simon de Lusignan; Maria Zambon Journal: Euro Surveill Date: 2015
Authors: Pratha Sah; Jan Medlock; Meagan C Fitzpatrick; Burton H Singer; Alison P Galvani Journal: Proc Natl Acad Sci U S A Date: 2018-04-30 Impact factor: 11.205